Clinical trials: Alzheimer Disease 1
Alzheimer's Disease
A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease
Pre-clinical studies have demonstrated that memantine can decrease the neuronal toxicity associated with excessive glutamate release and calcium overload in neurons.
- Trial name
- NCT00862940
- Testing
- Memantine
- Volunteers
- 277 people
- Sponsor
- H. Lundbeck A/S
Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
The study will be conducted in 2 blinded parts (Part 1 and Part 2). In Part 1, study participants who are mutation carriers will receive active donanemab and non-mutation carriers will receive placebo-donanemab for up to 18…
- Conditions
- Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease, Alzheimers Disease
- Trial name
- NCT06996730
- Testing
- Donanemab, RG6289
- Where
- Colombia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Banner Health
Alzheimer's Disease
Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.
This is a Phase 1, single center, open-label, non-randomized, clinical study in probable AD patients and HVs to evaluate the efficacy, safety and tolerability of a single dose of MNI-672.
- Trial name
- NCT01859767
- Testing
- [123I]MNI-672 SPECT
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer Disease, Alzheimer Disease, Early Onset
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild…
- Trial name
- NCT07221344
- Testing
- ARO-MAPT-SC
- Where
- 4 sites in Canada, New Zealand
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
HIV
Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.
The goal of this clinical trial is to test 16055 NFL delta Gly4 Env protein trimer and Trimer 4571 combined with 3M-052-AF + Alum adjuvant and Ad4-Env145NFL viral particles as heterologous prime-boost regimens in adult…
- Trial name
- NCT06332339
- Testing
- 16055 NFL delta Gly4 trimer, Trimer 4571, Ad4-Env145NFL, 5 x 108 viral particles (vp)
- Where
- 6 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Alzheimer Disease
Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects
Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of [C14] CT1812
- Trial name
- COG0108 (NCT05225389)
- Testing
- 300 mg [C14] CT1812
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cognition Therapeutics
Alzheimer Disease
Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease
This study is a Phase 1, first-in-human, multi-center study to establish safety of ADx-001 in healthy volunteers, and safety and proof of concept in patients with confirmed amyloid plaques in the brain (confirmed by amyloid…
- Trial name
- NCT05453539
- Testing
- DSPE-DOTA-Gd Liposomal Injection
- Where
- 2 sites in Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Alzeca Biosciences, Inc.
Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder)
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage.
- Conditions
- Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)
- Trial name
- NIO-SILK (NCT06372821)
- Testing
- NIO752
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 10 people
- Sponsor
- University College, London
Alzheimer Disease, Huntington Disease
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and…
- Trial name
- NCT00831506
- Testing
- digoxin, dimebon
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Biomarker Study: Heart Failure Patients at Risk
In order to determine if NfL can be a prognostic biomarker for VCID, participants will undergo a baseline evaluation consisting of neuropsychological testing and a blood draw with a 12-month follow-up consisting of…
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT05336175
- Testing
- Angiotensin 1-7, Saline solution
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Arizona
Healthy
Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults
Pharmacokinetics and safety of BPDO-1603 or BPDO-16031 and BPDO-16033 administration in healthy adults. Randomized, open-label, single-dose, cross-over, Phase 1 study
- Trial name
- NCT05804279
- Testing
- BPDO-1603
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hyundai Pharm
Alzheimer Disease
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
This Phase 1 study is a single ascending dose (SAD) and multiple ascending dose (MAD), placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous ACU193 when…
- Trial name
- INTERCEPT-AD (NCT04931459)
- Testing
- ACU193
- Where
- 17 sites in United States
- Volunteers
- 65 people
- Sponsor
- Acumen Pharmaceuticals
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Human Immunodeficiency Virus
Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women
A Phase I Single-Blind randomised trial investigating immunisation strategies using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA combinations in order to maximise antibody responses to Human Immunodeficiency Virus
- Trial name
- Ad4HIV (NCT03408262)
- Testing
- Ad4-EnvCN54, MVA-CN54, CN54gp140/MPLA
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Alzheimer Disease, Dementia
Technology and Family Thriving Study
The purpose of this project is to test the impact of different forms of technology (virtual reality vs. video chat) on quality of life and family relationships in older adults who reside in senior living communities and an adult…
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burnout, Quality of Life
- Trial name
- Thrive (NCT05150990)
- Testing
- Virtual Reality, Video Chat
- Where
- 27 sites in United States
- Volunteers
- 186 people
- Sponsor
- University of California, Santa Barbara
Diabetes (DM), Cardio Vascular Disease
Nut Consumption and Prevention of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis
The relationship between nut consumption and the risk of developing non-communicable diseases (NCDs) has been a subject of growing interest.
- Conditions
- Diabetes (DM), Cardio Vascular Disease, Cancer, Dementia
- Trial name
- NUTPOOL (NCT07205978)
- Where
- 2 sites in Denmark, Spain
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study
The goal of the study is to characterize preclinical Alzheimer's Disease and related dementias (AD/ADRD) neuropathology in a selected group of young adults with youth-onset diabetes, and an age-similar group of young adults…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes, Youth Onset
- Trial name
- NCT05350514
- Testing
- PI-2620 tracer
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Alzheimer Disease
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
This is a Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Multiple Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers and Subjects with MCI or…
- Trial name
- NCT06194552
- Testing
- NTRX-07
- Where
- 2 sites in United States, Hungary
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- NeuroTherapia, Inc.
Alzheimer's Disease, Healthy Volunteer
Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease
The primary objective of the study is to evaluate the safety and tolerability of single-ascending intravenous (IV) infusions of BIIB076 in healthy volunteers and participants with Alzheimer's disease (AD).
- Trial name
- NCT03056729
- Testing
- BIIB076
- Where
- 8 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Biogen
Familial Alzheimer Disease (FAD), PSEN1 Mutation
Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
The goal of this clinical trial is to learn about safety and efficacy of bromocriptine in familial Alzheimer's disease with presenilin 1 mutations.
- Trial name
- REBRAnD (NCT04413344)
- Testing
- Bromocriptine Mesilate
- Where
- 8 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kyoto University